Soligenix Inc (SNGX)

0.63
0.05 8.43
OTC : Health Care
Prev Close 0.58
Open 0.60
Day Low/High 0.58 / 0.69
52 Wk Low/High 0.44 / 1.49
Volume 123.51K
Avg Volume 97.00K
Exchange OTC
Shares Outstanding 33.58M
Market Cap 20.15M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS

Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS

Awarded $634,000 in additional contract funding

Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation

Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation

ThermoVax® Development Expands into Pandemic Infectious Disease

OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference

OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference

OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel "Understanding Reg A+ and the 'Mini IPO'"

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Awarded $3.2M to Conduct Preclincial Efficacy and Toxicology Studies

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Awarded $4.3M to Support Manufacturing Activities

Soligenix Announces Issuance Of New Patents For Dusquetide

Soligenix Announces Issuance Of New Patents For Dusquetide

Patents provide broad protection, including composition of matter claims

Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease

Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease

Preclinical Results Supported by Recent Positive Phase 2 Clinical Trial

Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results

Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results

Highlighted by Revenues of $8.8 Million

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Awarded $660,000 to accelerate regulatory interactions with FDA

Soligenix Provides 2016 Business Outlook

Soligenix Provides 2016 Business Outlook

Reviews 2015 Achievements and 2016 Milestones

Soligenix Receives Additional NIAID Funding To Advance Development Of OrbeShield™ In GI ARS

Soligenix Receives Additional NIAID Funding To Advance Development Of OrbeShield™ In GI ARS

Awarded $2.1 million in additional funding

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Awarded $2.7 million in additional funding

From Our Partners